IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It offers in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology, and coagulation analyzers; and SNAP rapid assays test kits. The company also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, it offers diagnostic tests, services, and related instrumentation for manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Strategic Positioning | Learn about IDEXX's strong market position in veterinary diagnostics and software, and its strategies to maintain industry leadership |
Analyst Projections | Average price target of $556, with estimates ranging from $481 to $630, reflecting varied views on IDEXX's growth potential |
Innovation Pipeline | Discover how IDEXX's new product launches, including inVue Dx and Cancer Dx, are positioning the company for potential long-term growth |
Market Resilience | Explore IDEXX's impressive financial metrics and stock performance amid veterinary visit fluctuations and macroeconomic challenges |
Metrics to compare | IDXX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIDXXPeersSector | |
---|---|---|---|---|
P/E Ratio | 45.8x | −2.7x | −0.5x | |
PEG Ratio | 9.55 | 0.02 | 0.00 | |
Price / Book | 28.3x | 2.6x | 2.6x | |
Price / LTM Sales | 10.4x | 3.4x | 2.9x | |
Upside (Analyst Target) | 0.5% | 63.9% | 51.4% | |
Fair Value Upside | Unlock | −5.3% | 9.5% | Unlock |